The NHLBI has stopped AIM-HIGH, a clinical trial studying a blood lipid treatment, 18 months earlier than planned. The trial found that adding high-dose, extended-release niacin to statin treatment in people with heart and vascular disease did not reduce the risk of cardiovascular events, including heart attacks and stroke. Read the full press release and related materials at http://www.nhlbi.nih.gov/new/prcurrent.htm.
Dr. Shurin discusses the early termination of the trial in the brief video below.
NHLBI Acting Director Susan B. Shurin, M.D., discusses findings of the AIM-HIGH study, why it was terminated early, and what it might mean for people currently taking niacin to manage cholesterol. Related press materials can be viewed at: http://www.nhlbi.nih.gov/new/prcurrent.htm